Expanded access to investigational drugs, biological products, and devices. (SB1222)

Introduced By

Sen. Bryce Reeves (R-Spotsylvania)

Progress

Introduced
Passed Committee
Passed House
Passed Senate
Signed by Governor
Became Law

Description

Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who has a terminal illness when (i) no comparable or satisfactory alternative treatment options approved by the U.S. Food and Drug Administration are available to treat his terminal illness; (ii) the potential benefits of the use of the investigational drug, biological product, or device outweigh the risks of use of the investigational drug, biological product, or device; (iii) his treating physician has recommended use of the investigational drug, biological product, or device; and (iv) the person has provided informed written consent to use of the investigational drug, biological product, or device. The bill provides that a manufacturer that provides an investigational drug, biological product, or device for treatment of a person's terminal illness may provide the investigational drug, biological product, or device free of charge or may require the person to pay costs associated with manufacture of the investigational drug, biological product, or device. The bill also provides that health insurance providers may, but are not required to, provide coverage for costs associated with use of the investigational drug, biological product, or device. Read the Bill »

Status

02/05/2015: Merged into SB732

History

DateAction
01/14/2015Prefiled and ordered printed; offered 01/14/15 15101338D
01/14/2015Referred to Committee on Education and Health
01/20/2015Assigned Education sub: Health Professions
01/28/2015Impact statement from VDH (SB1222)
02/05/2015Incorporated by Education and Health (SB732-Stanley) (14-Y 0-N) (see vote tally)